Veru (NASDAQ:VERU) Lowered to “Sell” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Veru (NASDAQ:VERU) from a hold rating to a sell rating in a research note released on Thursday morning, Zacks.com reports.

According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “

Several other equities research analysts have also issued reports on VERU. Brookline Capital Management started coverage on Veru in a research note on Monday, July 29th. They set a buy rating and a $12.00 price target for the company. ValuEngine raised Veru from a hold rating to a buy rating in a research note on Friday, May 10th. Cantor Fitzgerald started coverage on Veru in a research note on Monday, July 1st. They set an overweight rating and a $6.00 price target for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $4.50 price target on shares of Veru in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Veru presently has a consensus rating of Buy and an average price target of $5.71.

Shares of VERU stock opened at $1.89 on Thursday. The company has a quick ratio of 0.99, a current ratio of 1.47 and a debt-to-equity ratio of 0.13. The business has a 50-day moving average price of $2.19 and a two-hundred day moving average price of $1.74. Veru has a 12-month low of $1.18 and a 12-month high of $2.49. The firm has a market cap of $125.52 million, a P/E ratio of -4.85 and a beta of 0.37.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Veru had a negative return on equity of 50.14% and a negative net margin of 59.68%. The firm had revenue of $9.73 million during the quarter, compared to analyst estimates of $8.11 million. As a group, research analysts expect that Veru will post -0.18 EPS for the current fiscal year.

In other news, insider Mitchell Shuster Steiner sold 20,000 shares of Veru stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $2.25, for a total value of $45,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders sold 70,000 shares of company stock worth $152,400. Company insiders own 29.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Veru in the first quarter worth about $95,000. BlackRock Inc. increased its holdings in Veru by 9.3% during the 4th quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after purchasing an additional 10,956 shares during the period. Wedge Capital Management L L P NC purchased a new position in Veru during the 2nd quarter valued at about $394,000. Geode Capital Management LLC increased its holdings in Veru by 115.4% during the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after purchasing an additional 115,506 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Veru by 183.1% during the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock valued at $558,000 after purchasing an additional 169,550 shares during the period. Hedge funds and other institutional investors own 9.19% of the company’s stock.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Read More: How does a reverse stock split work?

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
$1.31 EPS Expected for Microchip Technology Inc.  This Quarter
$1.31 EPS Expected for Microchip Technology Inc. This Quarter
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
-$0.63 Earnings Per Share Expected for Instructure Inc  This Quarter
-$0.63 Earnings Per Share Expected for Instructure Inc This Quarter


© 2006-2019 Ticker Report